Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OncoSil™ plus FOLFIRINOX in locally advanced pancreatic cancer
NCT05466799Phase 2Active, not recruiting
- Sponsor
- OncoSil Medical
- Start
- Apr 2023
- Primary completion
- Jan 2026
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial in pancreatic adenocarcinoma (PDAC), sponsored by OncoSil Medical. Primary endpoints: Safety and Tolerability at 18 months and Local Disease Control Rate at 16 Weeks. Started Apr 2023; status: active, not recruiting.
02
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05466799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05466799.